Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Biotech Alert: Searches spiking for these stocks today » 11:07
10/07/22
10/07
11:07
10/07/22
11:07
MRSN

Mersana Therapeutics

$7.51 /

-0.02 (-0.27%)

, BHVN

Biohaven Pharmaceutical

$13.08 /

-0.16 (-1.21%)

, TCON

Tracon Pharmaceuticals

$1.75 /

-0.02 (-1.13%)

, SLRX

Salarius Pharmaceuticals

/

+

These names in the…

ShowHide Related Items >><<
TCON Tracon Pharmaceuticals
$1.75 /

-0.02 (-1.13%)

SLRX Salarius Pharmaceuticals
/

+

MRSN Mersana Therapeutics
$7.51 /

-0.02 (-0.27%)

BHVN Biohaven Pharmaceutical
$13.08 /

-0.16 (-1.21%)

MRSN Mersana Therapeutics
$7.51 /

-0.02 (-0.27%)

08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
05/10/22 Baird
Mersana Therapeutics price target lowered to $18 from $23 at Baird
05/09/22 H.C. Wainwright
Mersana price target lowered to $19 from $24 at H.C. Wainwright
11/10/21 Baird
Mersana Therapeutics price target lowered to $23 from $30 at Baird
BHVN Biohaven Pharmaceutical
$13.08 /

-0.16 (-1.21%)

08/18/22 Piper Sandler
Biohaven downgraded to Neutral from Overweight at Piper Sandler
08/08/22 Wedbush
Wedbush downgrades Biohaven to Neutral, sees Pfizer acquisition on track
08/08/22 Wedbush
Biohaven Pharmaceutical downgraded to Neutral from Outperform at Wedbush
05/23/22 Piper Sandler
Biohaven price target lowered to $149 from $170 at Piper Sandler
TCON Tracon Pharmaceuticals
$1.75 /

-0.02 (-1.13%)

02/23/22 Baird
Baird starts Tracon at Outperform, sees 70% odds of success for envafolimab
02/22/22 Baird
Tracon Pharmaceuticals initiated with an Outperform at Baird
12/27/21 Alliance Global Partners
Alliance Global says Tracon's higher dosing 'logical,' though will delay results
12/27/21 H.C. Wainwright
H.C. Wainwright reaffirms Buy on Tracon after IDMC recommends trial continue
SLRX Salarius Pharmaceuticals
/

+

03/11/22 H.C. Wainwright
Salarius Pharmaceuticals price target lowered to $4 from $5 at H.C. Wainwright
01/13/22 H.C. Wainwright
Salarius' pipeline has grown in diversification after deal, says H.C. Wainwright
12/29/21 H.C. Wainwright
H.C. Wainwright reiterates Buy on Salarius after dosing milestone reached
TCON Tracon Pharmaceuticals
$1.75 /

-0.02 (-1.13%)

SLRX Salarius Pharmaceuticals
/

+

MRSN Mersana Therapeutics
$7.51 /

-0.02 (-0.27%)

BHVN Biohaven Pharmaceutical
$13.08 /

-0.16 (-1.21%)

  • 19
    Jul
MRSN Mersana Therapeutics
$7.51 /

-0.02 (-0.27%)

BHVN Biohaven Pharmaceutical
$13.08 /

-0.16 (-1.21%)

Yesterday
Hot Stocks
Biohaven Pharmaceutical CEO buys $5.0M in common stock » 19:35
10/06/22
10/06
19:35
10/06/22
19:35
BHVN

Biohaven Pharmaceutical

$13.24 /

+0.98 (+7.99%)

In a regulatory filing,…

In a regulatory filing, Biohaven Pharmaceutical disclosed that its CEO Vlad Coric bought 486K shares of common stock on October 5th in a total transaction size of $5.0M.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$13.24 /

+0.98 (+7.99%)

BHVN Biohaven Pharmaceutical
$13.24 /

+0.98 (+7.99%)

08/18/22 Piper Sandler
Biohaven downgraded to Neutral from Overweight at Piper Sandler
08/08/22 Wedbush
Wedbush downgrades Biohaven to Neutral, sees Pfizer acquisition on track
08/08/22 Wedbush
Biohaven Pharmaceutical downgraded to Neutral from Outperform at Wedbush
05/23/22 Piper Sandler
Biohaven price target lowered to $149 from $170 at Piper Sandler
BHVN Biohaven Pharmaceutical
$13.24 /

+0.98 (+7.99%)

BHVN Biohaven Pharmaceutical
$13.24 /

+0.98 (+7.99%)

Hot Stocks
Mersana Therapeutics completes patient enrollment in UPLIFT trial » 16:11
10/06/22
10/06
16:11
10/06/22
16:11
MRSN

Mersana Therapeutics

$7.48 /

-0.28 (-3.61%)

Mersana Therapeutics…

Mersana Therapeutics announced the completion of patient enrollment in UPLIFT, the company's single-arm registrational trial of UpRi in platinum-resistant ovarian cancer. UpRi is Mersana's first-in-class NaPi2b-targeting ADC with a novel scaffold-linker-payload that enables a high drug-to-antibody ratio and controlled bystander effect.

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$7.48 /

-0.28 (-3.61%)

MRSN Mersana Therapeutics
$7.48 /

-0.28 (-3.61%)

08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
05/10/22 Baird
Mersana Therapeutics price target lowered to $18 from $23 at Baird
05/09/22 H.C. Wainwright
Mersana price target lowered to $19 from $24 at H.C. Wainwright
11/10/21 Baird
Mersana Therapeutics price target lowered to $23 from $30 at Baird
MRSN Mersana Therapeutics
$7.48 /

-0.28 (-3.61%)

MRSN Mersana Therapeutics
$7.48 /

-0.28 (-3.61%)

Hot Stocks
Biohaven Pharmaceutical rises 8.4% » 12:00
10/06/22
10/06
12:00
10/06/22
12:00
BHVN

Biohaven Pharmaceutical

$13.29 /

+1.03 (+8.40%)

Biohaven Pharmaceutical…

Biohaven Pharmaceutical is up 8.4%, or $1.03 to $13.28.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$13.29 /

+1.03 (+8.40%)

BHVN Biohaven Pharmaceutical
$13.29 /

+1.03 (+8.40%)

08/18/22 Piper Sandler
Biohaven downgraded to Neutral from Overweight at Piper Sandler
08/08/22 Wedbush
Wedbush downgrades Biohaven to Neutral, sees Pfizer acquisition on track
08/08/22 Wedbush
Biohaven Pharmaceutical downgraded to Neutral from Outperform at Wedbush
05/23/22 Piper Sandler
Biohaven price target lowered to $149 from $170 at Piper Sandler
BHVN Biohaven Pharmaceutical
$13.29 /

+1.03 (+8.40%)

BHVN Biohaven Pharmaceutical
$13.29 /

+1.03 (+8.40%)

On The Fly
Biotech Alert: Searches spiking for these stocks today » 11:10
10/06/22
10/06
11:10
10/06/22
11:10
KALV

KalVista

$5.01 /

-0.18 (-3.47%)

, CNTB

Connect Biopharma

$1.06 /

-0.02 (-1.85%)

, CUE

Cue Biopharma

$3.19 /

-0.04 (-1.24%)

, AUTL

Autolus Therapeutics

$3.00 /

+0.14 (+4.90%)

, BHVN

Biohaven Pharmaceutical

$12.37 /

+0.11 (+0.90%)

, BMY

Bristol-Myers

$70.25 /

-0.62 (-0.87%)

, PFE

Pfizer

$43.42 /

-0.7 (-1.59%)

These names in the…

ShowHide Related Items >><<
PFE Pfizer
$43.42 /

-0.7 (-1.59%)

KALV KalVista
$5.01 /

-0.18 (-3.47%)

CUE Cue Biopharma
$3.19 /

-0.04 (-1.24%)

CNTB Connect Biopharma
$1.06 /

-0.02 (-1.85%)

BMY Bristol-Myers
$70.25 /

-0.62 (-0.87%)

BHVN Biohaven Pharmaceutical
$12.37 /

+0.11 (+0.90%)

AUTL Autolus Therapeutics
$3.00 /

+0.14 (+4.90%)

KALV KalVista
$5.01 /

-0.18 (-3.47%)

10/06/22 H.C. Wainwright
KalVista price target lowered to $16 from $48 at H.C. Wainwright
10/05/22 H.C. Wainwright
H.C. Wainwright has more confidence in Astria opportunity after KalVista news
10/04/22 Piper Sandler
Piper says KalVista setback removes overhang for BioCryst's Orladeyo
06/08/22 Stifel
KalVista acute HAE market opportunity 'underappreciated,' says Stifel
CNTB Connect Biopharma
$1.06 /

-0.02 (-1.85%)

09/14/22 Piper Sandler
Connect Biopharma price target raised to $1.75 from $1.50 at Piper Sandler
06/02/22 Cantor Fitzgerald
Connect Biopharma initiated with an Overweight at Cantor Fitzgerald
05/05/22 Piper Sandler
Connect Biopharma downgraded to Neutral from Overweight at Piper Sandler
01/05/22 Piper Sandler
Connect Biopharma price target lowered to $25 from $31 at Piper Sandler
CUE Cue Biopharma
$3.19 /

-0.04 (-1.24%)

08/24/22 Oppenheimer
Cue Biopharma price target lowered to $10 from $26 at Oppenheimer
03/23/22 JMP Securities
Cue Biopharma price target lowered to $15 from $30 at JMP Securities
03/21/22 Oppenheimer
Cue Biopharma price target lowered to $26 from $32 at Oppenheimer
03/18/22 Craig-Hallum
Nektar failure 'not necessarily' a read through to Cue, says Craig-Hallum
AUTL Autolus Therapeutics
$3.00 /

+0.14 (+4.90%)

06/14/22 Truist
Autolus Therapeutics price target lowered to $11 from $13 at Truist
12/30/21 Mizuho
Mizuho announces top oncology stock picks for 2022
12/20/21 H.C. Wainwright
Autolus Therapeutics price target lowered to $11 from $13 at H.C. Wainwright
BHVN Biohaven Pharmaceutical
$12.37 /

+0.11 (+0.90%)

08/18/22 Piper Sandler
Biohaven downgraded to Neutral from Overweight at Piper Sandler
08/08/22 Wedbush
Wedbush downgrades Biohaven to Neutral, sees Pfizer acquisition on track
08/08/22 Wedbush
Biohaven Pharmaceutical downgraded to Neutral from Outperform at Wedbush
05/23/22 Piper Sandler
Biohaven price target lowered to $149 from $170 at Piper Sandler
BMY Bristol-Myers
$70.25 /

-0.62 (-0.87%)

09/16/22 Stifel
Ventyx Biosciences price target raised to $53 from $45 at Stifel
09/14/22 Berenberg
Berenberg downgrades Bristol-Myers to Hold into U.S. price reform risk
09/14/22 Berenberg
Bristol-Myers downgraded to Hold from Buy at Berenberg
09/12/22 Evercore ISI
Evercore expecting 'strong move' in Ventyx after Deucravacitinib label surprise
PFE Pfizer
$43.42 /

-0.7 (-1.59%)

09/20/22 Citi
Citi opens 'upside catalyst watch' on Alnylam Pharmaceuticals
09/13/22 Truist
Concert Pharmaceuticals price target raised to $25 from $22 at Truist
09/02/22 Cantor Fitzgerald
Cantor says ACIP recommendations support 'continued tail' for COVID-19 vaccines
08/26/22 Citi
Citi opens 'positive catalyst watches' on GSK, Sanofi after Zantac ruling
PFE Pfizer
$43.42 /

-0.7 (-1.59%)

KALV KalVista
$5.01 /

-0.18 (-3.47%)

CUE Cue Biopharma
$3.19 /

-0.04 (-1.24%)

BMY Bristol-Myers
$70.25 /

-0.62 (-0.87%)

BHVN Biohaven Pharmaceutical
$12.37 /

+0.11 (+0.90%)

AUTL Autolus Therapeutics
$3.00 /

+0.14 (+4.90%)

PFE Pfizer
$43.42 /

-0.7 (-1.59%)

BMY Bristol-Myers
$70.25 /

-0.62 (-0.87%)

PFE Pfizer
$43.42 /

-0.7 (-1.59%)

KALV KalVista
$5.01 /

-0.18 (-3.47%)

BMY Bristol-Myers
$70.25 /

-0.62 (-0.87%)

BHVN Biohaven Pharmaceutical
$12.37 /

+0.11 (+0.90%)

PFE Pfizer
$43.42 /

-0.7 (-1.59%)

BMY Bristol-Myers
$70.25 /

-0.62 (-0.87%)

Wednesday
Hot Stocks
Biohaven Pharmaceutical rises 26.2% » 12:00
10/05/22
10/05
12:00
10/05/22
12:00
BHVN

Biohaven Pharmaceutical

$10.50 /

+2.21 (+26.66%)

Biohaven Pharmaceutical…

Biohaven Pharmaceutical is up 26.2%, or $2.18 to $10.48.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$10.50 /

+2.21 (+26.66%)

BHVN Biohaven Pharmaceutical
$10.50 /

+2.21 (+26.66%)

08/18/22 Piper Sandler
Biohaven downgraded to Neutral from Overweight at Piper Sandler
08/08/22 Wedbush
Wedbush downgrades Biohaven to Neutral, sees Pfizer acquisition on track
08/08/22 Wedbush
Biohaven Pharmaceutical downgraded to Neutral from Outperform at Wedbush
05/23/22 Piper Sandler
Biohaven price target lowered to $149 from $170 at Piper Sandler
BHVN Biohaven Pharmaceutical
$10.50 /

+2.21 (+26.66%)

BHVN Biohaven Pharmaceutical
$10.50 /

+2.21 (+26.66%)

Tuesday
Conference/Events
Geron management to meet virtually with B. Riley » 13:53
10/04/22
10/04
13:53
10/04/22
13:53
GERN

Geron

$2.32 /

-0.055 (-2.32%)

Virtual Meetings to be…

Virtual Meetings to be held on October 12-13 hosted by B. Riley.

ShowHide Related Items >><<
GERN Geron
$2.32 /

-0.055 (-2.32%)

GERN Geron
$2.32 /

-0.055 (-2.32%)

07/28/22 B. Riley
Geron resumed with a Buy at B. Riley
11/01/21 Baird
Baird starts Geron at Outperform on 'strong outlook' for imetelstat
11/01/21 Baird
Geron initiated with an Outperform at Baird
GERN Geron
$2.32 /

-0.055 (-2.32%)

  • 30
    Mar
GERN Geron
$2.32 /

-0.055 (-2.32%)

Hot Stocks
Biohaven Pharmaceutical rises 15.4% » 12:00
10/04/22
10/04
12:00
10/04/22
12:00
BHVN

Biohaven Pharmaceutical

$8.07 /

+1.09 (+15.62%)

Biohaven Pharmaceutical…

Biohaven Pharmaceutical is up 15.4%, or $1.07 to $8.07.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$8.07 /

+1.09 (+15.62%)

BHVN Biohaven Pharmaceutical
$8.07 /

+1.09 (+15.62%)

08/18/22 Piper Sandler
Biohaven downgraded to Neutral from Overweight at Piper Sandler
08/08/22 Wedbush
Wedbush downgrades Biohaven to Neutral, sees Pfizer acquisition on track
08/08/22 Wedbush
Biohaven Pharmaceutical downgraded to Neutral from Outperform at Wedbush
05/23/22 Piper Sandler
Biohaven price target lowered to $149 from $170 at Piper Sandler
BHVN Biohaven Pharmaceutical
$8.07 /

+1.09 (+15.62%)

BHVN Biohaven Pharmaceutical
$8.07 /

+1.09 (+15.62%)

On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 10:00
10/04/22
10/04
10:00
10/04/22
10:00
GILD

Gilead

$64.21 /

+1.88 (+3.02%)

, DPZ

Domino's Pizza

$328.84 /

+12.485 (+3.95%)

, ILMN

Illumina

$201.32 /

+14.14 (+7.55%)

, COMM

CommScope

$10.95 /

+1.39 (+14.54%)

, BK

BNY Mellon

$41.08 /

+1.425 (+3.59%)

, PARA

Paramount

$19.77 /

+0.15 (+0.76%)

, SRAD

Sportradar

$8.45 /

-0.32 (-3.65%)

, MCG

Membership Collective

$3.47 /

-0.89 (-20.41%)

, MTB

M&T Bank

$184.94 /

+4.14 (+2.29%)

, WLK

Westlake

$91.80 /

+1.61 (+1.79%)

, AGTC

Applied Genetic

/

+

, SNX

TD Synnex

$86.77 /

+2.83 (+3.37%)

, GKOS

Glaukos

$55.96 /

+2.86 (+5.39%)

, DHX

DHI Group

$5.81 /

+0.165 (+2.93%)

, LFG

Archaea Energy

$19.93 /

+0.89 (+4.67%)

Institutional investors…

ShowHide Related Items >><<
WLK Westlake
$91.80 /

+1.61 (+1.79%)

SRAD Sportradar
$8.45 /

-0.32 (-3.65%)

SNX TD Synnex
$86.77 /

+2.83 (+3.37%)

PARA Paramount
$19.77 /

+0.15 (+0.76%)

MTB M&T Bank
$184.94 /

+4.14 (+2.29%)

MCG Membership Collective
$3.47 /

-0.89 (-20.41%)

LFG Archaea Energy
$19.93 /

+0.89 (+4.67%)

ILMN Illumina
$201.32 /

+14.14 (+7.55%)

GKOS Glaukos
$55.96 /

+2.86 (+5.39%)

GILD Gilead
$64.21 /

+1.88 (+3.02%)

DPZ Domino's Pizza
$328.84 /

+12.485 (+3.95%)

DHX DHI Group
$5.81 /

+0.165 (+2.93%)

COMM CommScope
$10.95 /

+1.39 (+14.54%)

BK BNY Mellon
$41.08 /

+1.425 (+3.59%)

AGTC Applied Genetic
/

+

GILD Gilead
$64.21 /

+1.88 (+3.02%)

10/04/22 JPMorgan
Gilead upgraded to Overweight from Neutral at JPMorgan
09/20/22 Piper Sandler
Piper says Merck partial hold being lifted a positive update for Gilead
09/15/22 Truist
Gilead price target raised to $76 from $71 at Truist
09/13/22 Wells Fargo
Gilead price target raised to $74 from $63 at Wells Fargo
DPZ Domino's Pizza
$328.84 /

+12.485 (+3.95%)

10/04/22 UBS
Domino's Pizza upgraded to Buy from Neutral at UBS
10/03/22 Oppenheimer
Domino's Pizza price target lowered to $415 from $445 at Oppenheimer
09/27/22 Cowen
Domino's Pizza price target lowered to $362 from $410 at Cowen
09/23/22 Citi
Domino's Pizza price target lowered to $415 from $475 at Citi
ILMN Illumina
$201.32 /

+14.14 (+7.55%)

10/04/22 SVB Securities
Illumina upgraded to Outperform from Market Perform at SVB Securities
10/04/22 Citi
Illumina long-term outlook in line with expectations, says Citi
09/30/22 Barclays
Illumina price target raised to $175 from $130 at Barclays
09/29/22 Piper Sandler
Piper says Illumina remains a top pick after NovaSeq X unveil
COMM CommScope
$10.95 /

+1.39 (+14.54%)

10/04/22 Credit Suisse
CommScope upgraded to Outperform from Neutral at Credit Suisse
08/05/22 Deutsche Bank
CommScope price target raised to $12 from $9 at Deutsche Bank
08/05/22 Citi
CommScope price target raised to $7 from $6 at Citi
08/05/22 Morgan Stanley
CommScope downgraded to Equal Weight from Overweight at Morgan Stanley
BK BNY Mellon
$41.08 /

+1.425 (+3.59%)

10/04/22 Citi
BNY Mellon upgraded to Buy from Neutral at Citi
10/04/22 Citi
BNY Mellon upgraded to Buy from Neutral at Citi
09/27/22 Deutsche Bank
BNY Mellon price target lowered to $44 from $46 at Deutsche Bank
08/12/22 Deutsche Bank
BNY Mellon price target raised to $46 from $42 at Deutsche Bank
PARA Paramount
$19.77 /

+0.15 (+0.76%)

10/04/22 Wells Fargo
Wells Fargo downgrades Paramount on 'crumbling' linear ecosystem
10/04/22 Wells Fargo
Paramount downgraded to Equal Weight from Overweight at Wells Fargo
08/15/22 Benchmark
Nexstar getting 75% stake in CW Network for 'free,' says Benchmark
08/05/22 Deutsche Bank
Paramount price target lowered to $32 from $35 at Deutsche Bank
SRAD Sportradar
$8.45 /

-0.32 (-3.65%)

10/04/22 BofA
Sportradar downgraded to Underperform from Neutral at BofA
10/04/22 BofA
Sportradar downgraded to Underperform from Neutral at BofA
08/18/22 Canaccord
Sportradar price target raised to $20 from $18 at Canaccord
08/18/22 Deutsche Bank
Sportradar price target raised to $16 from $13 at Deutsche Bank
MCG Membership Collective
$3.47 /

-0.89 (-20.41%)

10/04/22 BofA
Membership Collective double downgraded to Underperform from Buy at BofA
10/04/22 BofA
Membership Collective downgraded to Underperform from Buy at BofA
08/18/22 Citi
Membership Collective post-earnings selloff unjustified, says Citi
03/28/22 Citi
Membership Collective price target lowered to $14 from $18 at Citi
MTB M&T Bank
$184.94 /

+4.14 (+2.29%)

10/04/22 Citi
M&T Bank downgraded to Neutral from Buy at Citi
10/04/22 Citi
M&T Bank downgraded to Neutral from Buy at Citi
09/30/22 Citi
Citi removes three from North America Focus List, adds KLA Corp.
09/28/22 Wedbush
M&T Bank assumed with a Neutral at Wedbush
WLK Westlake
$91.80 /

+1.61 (+1.79%)

10/04/22 Citi
Westlake downgraded to Sell on slowing housing market at Citi
10/04/22 Citi
Westlake downgraded to Sell from Neutral at Citi
10/04/22 KeyBanc
Westlake price target lowered to $79 from $90 at KeyBanc
10/03/22 Credit Suisse
Westlake price target lowered to $110 from $120 at Credit Suisse
AGTC Applied Genetic
/

+

10/04/22 Wells Fargo
Applied Genetic downgraded to Equal Weight from Overweight at Wells Fargo
09/30/22 Stifel
Applied Genetic price target lowered to $3 from $10 at Stifel
09/30/22 H.C. Wainwright
Applied Genetic price target lowered to $16 from $24 at H.C. Wainwright
09/28/22 BTIG
Applied Genetic downgraded to Neutral from Buy at BTIG
SNX TD Synnex
$86.77 /

+2.83 (+3.37%)

10/04/22 RBC Capital
TD Synnex initiated with a Sector Perform at RBC Capital
09/28/22 Barrington
TD Synnex price target lowered to $98 from $106 at Barrington
09/28/22 Raymond James
TD Synnex price target lowered to $140 from $175 at Raymond James
09/27/22 Credit Suisse
TD Synnex price target lowered to $103 from $110 at Credit Suisse
GKOS Glaukos
$55.96 /

+2.86 (+5.39%)

10/04/22 Needham
Needham starts Glaukos at Buy, expects recent launches to drive share recovery
10/04/22 Needham
Glaukos initiated with a Buy at Needham
09/07/22 Piper Sandler
Glaukos shares reflect constructive iDose view, says Piper Sandler
08/04/22 Citi
Glaukos price target raised to $54 from $49 at Citi
DHX DHI Group
$5.81 /

+0.165 (+2.93%)

10/04/22 Barrington
DHI Group initiated with an Outperform at Barrington
05/05/22 B. Riley
DHI Group price target raised to $9 from $8.50 at B. Riley
02/09/22 B. Riley
DHI Group price target raised to $8.50 from $7.50 at B. Riley
01/03/22 B. Riley
iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
LFG Archaea Energy
$19.93 /

+0.89 (+4.67%)

10/04/22 Wells Fargo
Archaea Energy initiated with an Overweight at Wells Fargo
06/17/22 Barclays
Barclays starts Archaea Energy at Overweight on 'vast' growth potential
06/17/22 Barclays
Archaea Energy initiated with an Overweight at Barclays
03/07/22 Stifel
Archaea Energy initiated with a Buy and placed on Select List at Stifel
WLK Westlake
$91.80 /

+1.61 (+1.79%)

SRAD Sportradar
$8.45 /

-0.32 (-3.65%)

SNX TD Synnex
$86.77 /

+2.83 (+3.37%)

PARA Paramount
$19.77 /

+0.15 (+0.76%)

MTB M&T Bank
$184.94 /

+4.14 (+2.29%)

MCG Membership Collective
$3.47 /

-0.89 (-20.41%)

LFG Archaea Energy
$19.93 /

+0.89 (+4.67%)

ILMN Illumina
$201.32 /

+14.14 (+7.55%)

GKOS Glaukos
$55.96 /

+2.86 (+5.39%)

GILD Gilead
$64.21 /

+1.88 (+3.02%)

DPZ Domino's Pizza
$328.84 /

+12.485 (+3.95%)

DHX DHI Group
$5.81 /

+0.165 (+2.93%)

COMM CommScope
$10.95 /

+1.39 (+14.54%)

BK BNY Mellon
$41.08 /

+1.425 (+3.59%)

  • 14
    Jul
  • 23
    Mar
  • 22
    Mar
PARA Paramount
$19.77 /

+0.15 (+0.76%)

ILMN Illumina
$201.32 /

+14.14 (+7.55%)

WLK Westlake
$91.80 /

+1.61 (+1.79%)

SRAD Sportradar
$8.45 /

-0.32 (-3.65%)

SNX TD Synnex
$86.77 /

+2.83 (+3.37%)

PARA Paramount
$19.77 /

+0.15 (+0.76%)

MTB M&T Bank
$184.94 /

+4.14 (+2.29%)

MCG Membership Collective
$3.47 /

-0.89 (-20.41%)

LFG Archaea Energy
$19.93 /

+0.89 (+4.67%)

ILMN Illumina
$201.32 /

+14.14 (+7.55%)

GKOS Glaukos
$55.96 /

+2.86 (+5.39%)

GILD Gilead
$64.21 /

+1.88 (+3.02%)

DPZ Domino's Pizza
$328.84 /

+12.485 (+3.95%)

DHX DHI Group
$5.81 /

+0.165 (+2.93%)

COMM CommScope
$10.95 /

+1.39 (+14.54%)

BK BNY Mellon
$41.08 /

+1.425 (+3.59%)

AGTC Applied Genetic
/

+

PARA Paramount
$19.77 /

+0.15 (+0.76%)

ILMN Illumina
$201.32 /

+14.14 (+7.55%)

GILD Gilead
$64.21 /

+1.88 (+3.02%)

DPZ Domino's Pizza
$328.84 /

+12.485 (+3.95%)

BK BNY Mellon
$41.08 /

+1.425 (+3.59%)

Hot Stocks
Biohaven launches as a new publicly traded company » 07:39
10/04/22
10/04
07:39
10/04/22
07:39
BHVN

Biohaven Pharmaceutical

$6.98 /

+0.68 (+10.79%)

, PFE

Pfizer

$44.12 /

+0.29 (+0.66%)

, ALNY

Alnylam

$196.84 /

-3.605 (-1.80%)

, BMY

Bristol-Myers

$70.54 /

-0.58 (-0.82%)

Biohaven (BHVN) launched…

Biohaven (BHVN) launched as a new publicly traded company. As of today, Biohaven has officially begun operating as a separate independent entity as part of the acquisition agreement with Pfizer (PFE) in May 2022. The company, led by Vlad Coric, M.D. as Chairman and Chief Executive Officer, launched with approximately $257.8 million in cash at the distribution and no debt. Biohaven has a history of successful drug development and commercialization. The FDA filed and accepted for review Biohaven's New Drug Application submission for zavegepant nasal spray with a Prescription Drug User Fee Act goal date set for the first quarter of 2023. With the acquisition by Pfizer for a total consideration of approximately $13B including payoff of existing debt, Pfizer will now exclusively commercialize and develop the Biohaven CGRP franchise globally. Pfizer owns approximately 3% of the new spinoff company Biohaven. Advancing a Broad Portfolio of Innovative Candidates: Biohaven plans to advance a broad portfolio of early- and late-stage innovative product candidates targeting neurological and neuropsychiatric diseases, including rare disorders with unmet medical needs. Therapeutic development will focus on treatments for epilepsy, pain and mood disorders, obsessive compulsive disorder, spinocerebellar ataxia and spinal muscular atrophy. Key clinical development programs underway that leverage these proprietary technology platforms, include the following: Glutamate modulation for SCA and OCD; Myostatin inhibition for neuromuscular diseases, and potentially for diabetes and weight loss; Novel immune modulation platform targeting CD-38 for multiple myeloma Team executives: The Biohaven Board of Directors remains the same. Irfan Qureshi, M.D. is promoted to Chief Medical Officer, previously Senior Vice President of Neurology at Biohaven. And Tanya Fischer, M.D., Ph.D. is appointed Chief Development Officer and Head of Translational Medicine, previously at Alnylam Pharmaceuticals (ALNY). Bruce Car, Ph.D. joins Biohaven as the new Chief Scientific Officer. Dr. Car brings more than 28 years of experience in the pharmaceutical industry having held numerous scientific leadership positions at Bristol-Myers Squibb (BMY).

ShowHide Related Items >><<
PFE Pfizer
$44.12 /

+0.29 (+0.66%)

BMY Bristol-Myers
$70.54 /

-0.58 (-0.82%)

BHVN Biohaven Pharmaceutical
$6.98 /

+0.68 (+10.79%)

ALNY Alnylam
$196.84 /

-3.605 (-1.80%)

BHVN Biohaven Pharmaceutical
$6.98 /

+0.68 (+10.79%)

08/18/22 Piper Sandler
Biohaven downgraded to Neutral from Overweight at Piper Sandler
08/08/22 Wedbush
Wedbush downgrades Biohaven to Neutral, sees Pfizer acquisition on track
08/08/22 Wedbush
Biohaven Pharmaceutical downgraded to Neutral from Outperform at Wedbush
05/23/22 Piper Sandler
Biohaven price target lowered to $149 from $170 at Piper Sandler
PFE Pfizer
$44.12 /

+0.29 (+0.66%)

09/20/22 Citi
Citi opens 'upside catalyst watch' on Alnylam Pharmaceuticals
09/13/22 Truist
Concert Pharmaceuticals price target raised to $25 from $22 at Truist
09/02/22 Cantor Fitzgerald
Cantor says ACIP recommendations support 'continued tail' for COVID-19 vaccines
08/26/22 Citi
Citi opens 'positive catalyst watches' on GSK, Sanofi after Zantac ruling
ALNY Alnylam
$196.84 /

-3.605 (-1.80%)

10/03/22 Jefferies
Alnylam price target raised to $232 from $218 at Jefferies
10/03/22 Citi
Alnylam update supports approvability of Onpattro, says Citi
09/20/22 RBC Capital
Alnylam price target raised to $250 from $225 at RBC Capital
BMY Bristol-Myers
$70.54 /

-0.58 (-0.82%)

09/16/22 Stifel
Ventyx Biosciences price target raised to $53 from $45 at Stifel
09/14/22 Berenberg
Berenberg downgrades Bristol-Myers to Hold into U.S. price reform risk
09/14/22 Berenberg
Bristol-Myers downgraded to Hold from Buy at Berenberg
09/12/22 Evercore ISI
Evercore expecting 'strong move' in Ventyx after Deucravacitinib label surprise
PFE Pfizer
$44.12 /

+0.29 (+0.66%)

BMY Bristol-Myers
$70.54 /

-0.58 (-0.82%)

BHVN Biohaven Pharmaceutical
$6.98 /

+0.68 (+10.79%)

ALNY Alnylam
$196.84 /

-3.605 (-1.80%)

PFE Pfizer
$44.12 /

+0.29 (+0.66%)

BMY Bristol-Myers
$70.54 /

-0.58 (-0.82%)

PFE Pfizer
$44.12 /

+0.29 (+0.66%)

BMY Bristol-Myers
$70.54 /

-0.58 (-0.82%)

BHVN Biohaven Pharmaceutical
$6.98 /

+0.68 (+10.79%)

ALNY Alnylam
$196.84 /

-3.605 (-1.80%)

PFE Pfizer
$44.12 /

+0.29 (+0.66%)

BMY Bristol-Myers
$70.54 /

-0.58 (-0.82%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.